JP2013507449A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507449A5
JP2013507449A5 JP2012534299A JP2012534299A JP2013507449A5 JP 2013507449 A5 JP2013507449 A5 JP 2013507449A5 JP 2012534299 A JP2012534299 A JP 2012534299A JP 2012534299 A JP2012534299 A JP 2012534299A JP 2013507449 A5 JP2013507449 A5 JP 2013507449A5
Authority
JP
Japan
Prior art keywords
amino
pyrimidin
phenyl
yloxy
pyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012534299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052385 external-priority patent/WO2011046970A1/en
Publication of JP2013507449A publication Critical patent/JP2013507449A/ja
Publication of JP2013507449A5 publication Critical patent/JP2013507449A5/ja
Pending legal-status Critical Current

Links

JP2012534299A 2009-10-12 2010-10-12 TBK1および/またはIKKεの阻害剤としてのアミノ−ピリミジン化合物 Pending JP2013507449A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25084209P 2009-10-12 2009-10-12
US61/250,842 2009-10-12
US32524510P 2010-04-16 2010-04-16
US61/325,245 2010-04-16
PCT/US2010/052385 WO2011046970A1 (en) 2009-10-12 2010-10-12 Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon

Publications (2)

Publication Number Publication Date
JP2013507449A JP2013507449A (ja) 2013-03-04
JP2013507449A5 true JP2013507449A5 (enExample) 2013-11-28

Family

ID=43500020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012534299A Pending JP2013507449A (ja) 2009-10-12 2010-10-12 TBK1および/またはIKKεの阻害剤としてのアミノ−ピリミジン化合物

Country Status (11)

Country Link
US (2) US20120238540A1 (enExample)
EP (1) EP2488503A1 (enExample)
JP (1) JP2013507449A (enExample)
KR (1) KR20120114224A (enExample)
CN (1) CN102791697A (enExample)
AU (1) AU2010306927A1 (enExample)
BR (1) BR112012008677A2 (enExample)
CA (1) CA2777762A1 (enExample)
MX (1) MX2012004313A (enExample)
NZ (1) NZ599826A (enExample)
WO (1) WO2011046970A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201012105D0 (en) * 2010-07-19 2010-09-01 Domainex Ltd Novel pyrimidine compounds
EP2693881B1 (en) * 2011-04-01 2019-09-04 University of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
EP2696683A4 (en) * 2011-04-12 2014-08-13 Alzheimer S Inst Of America Inc COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER
ES2613103T3 (es) 2011-04-19 2017-05-22 Bayer Intellectual Property Gmbh 4-Aril-n-fenil-1,3,5-triacin-2-aminas sustituidas
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
CA2848616A1 (en) 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
CN103930399B (zh) 2011-09-16 2016-03-16 拜耳知识产权有限责任公司 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
US9045493B2 (en) * 2012-02-09 2015-06-02 Merck Patent Gmbh Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives
WO2013175415A1 (en) * 2012-05-23 2013-11-28 Piramal Enterprises Limited Substituted pyrimidine compounds and uses thereof
WO2014055624A1 (en) * 2012-10-02 2014-04-10 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
ES2595222T3 (es) 2012-10-18 2016-12-28 Bayer Pharma Aktiengesellschaft Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona
EP2909183B1 (en) 2012-10-18 2016-08-24 Bayer Pharma Aktiengesellschaft 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物
EP2941428A1 (en) * 2013-01-07 2015-11-11 Vichem Chemie Kutató KFT 4-pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (plk1) for the treatment of cancer and their use for the treatment of bacterial infections
GB201303109D0 (en) * 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
RU2019119893A (ru) 2013-03-14 2019-08-09 Толеро Фармасьютикалз, Инк. Ингибиторы jak2 и alk2 и способы их использования
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2016049211A1 (en) * 2014-09-26 2016-03-31 Gilead Sciences, Inc. Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CN107207475A (zh) 2014-10-16 2017-09-26 拜耳医药股份有限公司 含有砜基团的氟化苯并呋喃基‑嘧啶衍生物
US20160263183A1 (en) * 2015-03-10 2016-09-15 Brown University Methods for treating lung disease
CA2980507A1 (en) 2015-03-24 2016-09-29 Public University Corporation Nagoya City University Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas
US20180078560A1 (en) 2015-03-24 2018-03-22 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
WO2016150902A1 (en) 2015-03-24 2016-09-29 Bayer Pharma Aktiengesellschaft Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
WO2016210331A1 (en) * 2015-06-26 2016-12-29 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors
HK1254835A1 (zh) * 2015-06-26 2019-07-26 卡德门企业有限公司 葡萄糖摄取抑制剂
ES2786552T3 (es) 2015-09-29 2020-10-13 Bayer Pharma AG Compuestos de sulfondiimina macrocíclicos nuevos
ES2819869T3 (es) 2015-10-08 2021-04-19 Bayer Pharma AG Nuevos compuestos macrocíclicos modificados
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CN105503626A (zh) * 2015-12-12 2016-04-20 常州大学 一种2-氨基-4-氯-6-甲氧基苯酚的合成方法
KR20180094976A (ko) 2015-12-17 2018-08-24 길리애드 사이언시즈, 인코포레이티드 Tank-결합 키나제 억제제 화합물
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
TWI680122B (zh) * 2016-09-07 2019-12-21 國立陽明大學 活化腺苷單磷酸活化蛋白激酶之化合物
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
CA3057892A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
MY198379A (en) 2017-07-28 2023-08-28 Yuhan Corp Improved Process for Preparing Aminopyrimidine Derivatives
CA3078579A1 (en) * 2017-10-17 2019-04-25 Merck Patent Gmbh Pyrimidine tbk/ikk.epsilon. inhibitor compounds and uses thereof
EP3697773A1 (en) 2017-10-17 2020-08-26 Merck Patent GmbH PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
CN109912514B (zh) * 2017-12-13 2022-11-18 广东东阳光药业有限公司 (2-杂芳基胺基苯基)氮杂环衍生物及其用途
SG11202006470RA (en) 2018-02-13 2020-08-28 Bayer Ag Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
KR20210003780A (ko) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
US12030857B2 (en) 2018-06-25 2024-07-09 Kadmon Corporation, Llc Glucose uptake inhibitors
KR20210038906A (ko) 2018-07-26 2021-04-08 스미토모 다이니폰 파마 온콜로지, 인크. 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN111269215B (zh) * 2020-04-01 2021-10-26 中科利健制药(广州)有限公司 含氮杂环有机化合物及其制备方法和应用
CN112142675B (zh) * 2020-10-09 2021-11-30 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的小分子化合物及其用途
EP4472953A1 (en) * 2022-02-03 2024-12-11 Nexys Therapeutics, Inc. Aryl hydrocarbon receptor agonists and uses thereof
CN117247387A (zh) * 2022-06-16 2023-12-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途
WO2025096505A1 (en) * 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5149820A (en) 1987-03-11 1992-09-22 Norsk Hydro A.S. Deuterated compounds
CA2148931A1 (en) * 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
DE10162120A1 (de) 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Dihydrofuranone sowie diese Verbindungen enthaltende Arzneimittel
US7348335B2 (en) * 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
GT200500286A (es) * 2004-10-13 2006-06-13 Analogos de anilino-pirimidina
US20080153822A1 (en) * 2006-11-30 2008-06-26 Martin Augustin Methods of treating pain
FR2911139A1 (fr) * 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
BRPI0806811A2 (pt) * 2007-01-23 2011-09-13 Palau Pharma Sa derivados de purina
MX2009009792A (es) * 2007-03-12 2009-09-23 Cytopia Res Pty Ltd Compuestos de fenil amino pirimidina y usos de los mismos.
WO2009030890A1 (en) * 2007-09-03 2009-03-12 University Court Of The University Of Dundee Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma
CA2698511C (en) * 2007-09-04 2016-10-11 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2283024B1 (en) * 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2013507449A5 (enExample)
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
RU2411238C2 (ru) Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
US10183025B2 (en) Autotaxin inhibitors
RU2401265C2 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP2014511869A5 (enExample)
TWI415845B (zh) 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
RU2009126624A (ru) Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
KR101855358B1 (ko) 골암통증에서의 시그마 리간드의 용도
RU2010115574A (ru) Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток
JP2021501179A5 (enExample)
JP2010540452A5 (enExample)
JP2007523905A5 (enExample)
JP2009537543A5 (enExample)
JP2007519754A5 (enExample)
JP2018527336A5 (enExample)
CN102686563A (zh) 取代的苯甲酰胺衍生物
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
RU2007127834A (ru) Производные 1, 6-замещенного (3r, 6r)-3-(2, 3-дигидро-1н-инден-2-ил)-2, 5-пиперазиндиона в качестве антагонистов рецептора окситоцина для лечения преждевременных родов, дисменореи и эндометриоза
KR20110119790A (ko) 당뇨병 및 비만을 치료하는데 tgr5 효능제로서 사용되는 트리아졸 및 이미다졸 유도체
RU2011127232A (ru) Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2016503009A5 (enExample)
RU2014121984A (ru) Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
JP2013510876A5 (enExample)